Follow Us:Respiratio 2017; 7 (1-2): 65-71
METABOLIČKI SINDROM KOD BOLESNIKA SA HRONIČNOM
OPSTRUKTIVNOM BOLEŠĆU PLUĆA: UČESTALOST I POVEZANOST
SA KLINIČKIM KARAKTERISTIKAMA
METABOLIC SYNDROME IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY
DISEASE: FREQUENCY AND RELATIONSHIP WITH CLINICAL CHARACTERISTICS
Tatjana Vujić¹, Gorica Marić², Ljudmila Nagorni Obradović³, Snežana Cvetković¹
¹Klinika za pulmologiju, Klinički centar Srbije, Beograd, Srbija
²Institute of Epidemiology, Faculty of Medicine , University of Belgrade , Belgrade , Serbia
³ Faculty of Medicine, University of Belgrade, Belgrade,Serbia
Original Research
Naučni članak
SAŽETAK
Uvod: Metabolički sindrom (MetS) je čest kod bolesnika sa hroničnom opstruktivnom
bolešću pluća (HOBP). Sistemska inflamacija igra važnu ulogu i u HOBP i u MetS-u. Cilj studije je bio da se proceni učestalost MetS-a kod bolesnika sa HOBP i da se evaluišu razlike između bolesnika sa HOBP i MetS-om i bolesnika sa HOBP bez MetS-a u odnosu na demografske i kliničke karakteristike kao i stepen inflamacije.
Metode: Studija preseka je obuhvatila 115 bolesnika sa stabilnom HOBP. MetS je definisan prema kriterijumima Međunarodne federacije za dijabetes. Kod svih bolesnika su određene komponente MetS-a i C-reaktivni protein (CRP), učinjena je spirometrija. Klasifikacija HOBP je načinjena prema kriterijumima Globalne inicijative za hroničnu opstruktivnu bolest pluća- GOLD.
Rezultati: MetS je prisutan kod 35,65% bolesnika sa HOBP. Učestalost MetS-a kod bolesnika u GOLD stadijumima I, II, III, IV je bila 50,0%; 44,9%; 29,3%; 17,6% (redom). Nije bilo razlika između bolesnika sa HOBP i MetS-om i bolesnika sa HOBP bez MetS-a u odnosu na starost, pušenje i dužinu HOBP. Bolesnici sa HOBP i MetS-om su pokazali značajno viši nivo CRP-a.
Zaključak: studija pokazuje da je MetS čest kod bolesnika sa HOBP. Nivo CRP-a je značajno viši kod bolesnika sa HOBP koji imaju MetS nego kod bolesnika sa HOBP bez MetS-a. Ovi nalazi sugerišu da je potreban skrining bolesnika sa HOBP za pridruženi MetS i povišene markere inflamacije, u cilju kontrolisanja ovih komponenti i posledičnog smanjenja rizika od kardiovaskularnog morbiditeta I mortaliteta kod ovih bolesnika.
Ključne reči: Hronična opstruktivna bolest pluća, Metabolički sindrom, C- reaktivni protein
LITERATURA
|
1. Pauwels RA, Rabe KF. Burden and clinical featuresof chronic obstructive pulmonary disease (COPD). Lancet. 2004; 364:613-620. |
|
|
|
|
|
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. 2017 Report Available on: www.goldcopd.com |
|
|
|
|
|
3. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009; 33: 1165-1185 |
|
|
|
|
|
4. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J. 2003; 21(2): 347-360. |
|
|
|
|
|
5. Gan WQ, Man SF, Senthilselvan A, Sinn DD. Association between chronic obstructive pulmonary disease and systemic inflammation: a systemic review and a metaanalysis. Thorax. 2004; 59;574-580 |
|
|
|
|
|
6. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al; International Diabetes Federation Task Force on Epidemiology and Prevention; Hational Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention;National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120: 1640-1645 |
|
|
|
|
|
7. Wells CE, Baker EH. Metabolic syndrome and diabetes mellitus in COPD. Rabe KF, Wedzicha JA, Wouters EFM (eds). COPD and Comorbidity. European Respiratory Society, Sheffield, 2013, 117-134. |
|
|
|
|
|
8. Alberti KG, Zimmer P, Shaw J. Metabolic syndrome- a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med.2006; 23: 469-480. |
|
|
|
|
|
9. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R,Yemault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J.1993; Suppl.16:5-40. |
|
|
|
|
|
10. Pickering TG, Hall JE, Appel LJ, Falkner BE, Graves J, Hill MN, et al. Recommendations for Blood Pressure Measurement in Humans and Experimental Animals. Part1: Blood Pressure Measurement in Humans. A Statement for Professionals From the Subcommittee of Professionals and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005; 45:142-161 |
|
|
|
|
|
11. Watz H, Waschki B, Kirsten A, Muller K, Kretchmar G, Meyer T, et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest. 2009; 136: 1039-1046. |
|
|
|
|
|
12. Minas M, Kostikas K, Papaioannou AI, Mystridou P, Karetsi E, Georgoulias P, et al. The association of metabolic syndrome with adipose tissue hormones and insulin resistance in patients with COPD without comorbidities. COPD. 2011; 8: 414-420. |
|
|
|
|
|
13. Lam KBH, Jordan RE, Jiang CQ, Thomas GN, Miller MR, Zhang WS, et al. Airflow obstruction and metabolic syndrome: the Guangzhou Biobank Cohort Study. Eur Respir J.2010; 35: 317-323. |
|
|
|
|
|
14. Funakoshi Y, Omori H, Mihara S, Marubayashi T, Katoh T. Association between airflow obstruction and the metabolic syndrome and its components in Japanese men. Intern Med. 2010; 49: 2093-2099. |
|
|
|
|
|
15. Hosny H, Abdel-Hafiz H, Moussa H, Soliman A. Metabolic syndrome and systemic inflammation in patients with chronic obstructive pulmonary disease. Egyptian Journal of Chest Diseases and Tuberculosis. 2013; 62: 85-89. |
|
|
|
|
|
16. Akpinar EE, Akpinar S, Ertek S, Sayin E, Gulhan M. Systemic inflammation and metabolic syndrome in stable COPD patients. Turbek Toraks. 2012; 60, 3:230-237. |
|
|
|
|
|
17. Diez-Manglano J, Barquero-Romero J, Almagro P, Cabrera FJ, Garcia FL, Montero L, et al . COPD patients with and without metabolic syndrome:clinical and functional differences. Intern Emerg Med. 2014; 9: 419-425. |
|
|
|
|
|
18. Stanciu S, Marinescu R, Iordache M, Dumitrescu S, Muresan M, Bogdan MA. Are systemic inflammatory profiles different in patients with COPD and metabolic syndrome as compared to those with COPD alone? Rom J Intern Med. 2009;47, 4: 381-386. |
|
|
|
|
|
19. Mekov E, Slavova Y, Tsakova A, Genova M,Kostadinov D, Minchev D, et al . Metabolic syndrome in hospitalized patients with chronic obstructive pulmonary disease. PeerJ. 2015; 3:e1068; |
|
|
|
|
|
20. Skrbic D. Metabolic syndrome in patients with chronic obstructive pulmonary disease (dissertation) (Novi Sad): University of Novi Sad. 2015;192 p |
|
|
|
|
|
21. Breyer M-K, Spruit MA, Hanson CK, Franssen FME, Vanfleteren LEGW, Groenen MTJ, et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLOS ONE. 2014; 9(6):e98013. |
|
|
|
|
|
22. Park SK, Larson JL. Metabolic syndrome and associated factors in people with chrobstructive pulmonary disease. West J Nurs Res. 2014; 36 (5):620-42 |
|
|
|
|
|
23. Ozgen Alpaydin A, Konyar Arslan I, Serter S, Sakar Coskun A, Celik P, Taneli F et al. Metabolic syndrome and carotid intima-media thickness in chronic obstructive pulmonary disease. Multidisciplinary Respiratory Medicine. 2013; 8:61. |
|
Submitted: April 10th, 2017
Accepted: May 10th, 2017
Tatjana Vujic,
Klinika za pulmologiju,
Klinički centar Srbije,
Koste Todorovica 26, 11000 Beograd, Srbija;
tel. +381113663491, mob. +381641364074,
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.